They are generally divided into four major molecular subtypes: Luminal A and Luminal B (~30–70% of cases of breast cancers), HER2 tumors (~30%) and triple negative breast cancer (TNBC; ~15–20%), a BC subtype characterized by the lack of ER, PR and HER2 expression. This evidence concerns the gene ERBB2 and breast carcinoma.